Research Article

A Bioinformatic Approach Based on Systems Biology to Determine the Effects of SARS-CoV-2 Infection in Patients with Hypertrophic Cardiomyopathy

Xiao Han\textsuperscript{1}, Fei Wang\textsuperscript{2}, Ping Yang\textsuperscript{3}, Bin Di\textsuperscript{1}, Xiangdong Xu\textsuperscript{1}, Chunya Zhang\textsuperscript{1}, Man Yao\textsuperscript{1}, Yaping Sun\textsuperscript{1}, and Yangyi Lin\textsuperscript{4}

\textsuperscript{1}Department of Cardiology, Jiading District Central Hospital Affiliated Shanghai University of Medicine & Health Sciences, Shanghai, China
\textsuperscript{2}Department of Emergency Medicine, Jiading District Central Hospital Affiliated Shanghai University of Medicine & Health Sciences, Shanghai, China
\textsuperscript{3}Department of Pharmacy, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China
\textsuperscript{4}Department of Pulmonary Vascular Disease, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Correspondence should be addressed to Ping Yang; yangping@xinhuamed.com.cn

Received 10 August 2022; Revised 26 August 2022; Accepted 1 September 2022; Published 27 September 2022

Academic Editor: Min Tang

Copyright © 2022 Xiao Han et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Recently, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has infected millions of individuals worldwide. While COVID-19 generally affects the lungs, it also damages other organs, including those of the cardiovascular system. Hypertrophic cardiomyopathy (HCM) is a common genetic cardiovascular disorder. Studies have shown that HCM patients with COVID-19 have a higher mortality rate; however, the reason for this phenomenon is not yet elucidated. Herein, we conducted transcriptomic analyses to identify shared biomarkers between HCM and COVID-19 to bridge this knowledge gap. Differentially expressed genes (DEGs) were obtained using the Gene Expression Omnibus ribonucleic acid (RNA) sequencing datasets, GSE147507 and GSE89714, to identify shared pathways and potential drug candidates. We discovered 30 DEGs that were common between these two datasets. Using a combination of statistical and biological tools, protein-protein interactions were constructed in response to these findings to support hub genes and modules. We discovered that HCM is linked to COVID-19 progression based on a functional analysis under ontology terms. Based on the DEGs identified from the datasets, a coregulatory network of transcription factors, genes, proteins, and microRNAs was also discovered. Lastly, our research suggests that the potential drugs we identified might be helpful for COVID-19 therapy.

1. Introduction

It has been determined that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel member of the Coronaviridae family and the class of Pioniviricetes, causes mild and severe respiratory diseases in humans [1–4]. Even though SARS-CoV-2 infections primarily affect the respiratory tract, they frequently cause heart injuries in patients with moderate to severe coronavirus disease 2019 (COVID-19), particularly in those with underlying cardiovascular diseases [5–7]. Furthermore, growing evidence demonstrates a link between COVID-19 and increased mortality from heart failure and cardiovascular diseases [8].

Hypertrophic cardiomyopathy (HCM) is one of the most prevalent inherited heart conditions associated with angiotensin-converting enzyme 2 (ACE2) deficiency in patients with heart failure [9, 10]. SARS-CoV-2 binds with ACE2 and accelerates its degradation, thereby decreasing its ability to counteract the activity of the renin-angiotensin system (RAS) protein [11]. Although the present
results suggested that ACE2 expression increased with ACE inhibitor treatment in HCM patients’ tissues, they were not statistically significant [12]. Therefore, understanding the impact of SARS-CoV-2 infection in patients with HCM and developing therapeutic drugs that could decrease the odds of complications or death are essential. However, current efforts mainly focus on studying stress cardiomyopathies secondary to COVID-19, such as takotsubo cardiomyopathy [13, 14]. To date, no bioinformatic research on the impact of COVID-19 in patients with preexisting HCM at the molecular level has been reported.

Herein, to bridge the knowledge gap, the cooccurrence of HCM and COVID-19 was examined using two datasets, GSE89714 (HCM) and GSE147507 (COVID-19), obtained from the Gene Expression Omnibus (GEO) database. We identified the differentially expressed genes (DEGs) in each dataset and searched for DEGs shared by the two diseases. These common DEGs, designated as the primary experimental genes, were also used to identify various transcriptional regulators. Then, the hub genes were extracted from these common DEGs using the specific algorithm in the Cytoscape programme. Additionally, the hub genes were used to predict potential therapeutic drugs. Overall, we predicted four agents that could be potentially therapeutic for HCM patients with COVID-19.

2. Materials and Methods

2.1. Study Datasets. The National Center for Biotechnology Information (https://www.ncbi.nlm.nih.gov/geo/) and GEO databases were used to obtain the COVID-19 and HCM ribonucleic acid sequencing (RNA-seq) datasets [15]. The following criteria were used to assess the quality of the eligible datasets: (1) case-control study; (2) high-throughput sequencing for expression profiling; (3) comparable experimental and control or untreated conditions; (4) more than three samples in each group; and (5) complete raw and processed microarray data was available. The high-throughput Illumina NextSeq 500 RNA sequencing platform was used to obtain the transcriptional profiles of lung biopsy samples from patients with COVID-19 for the GSE147507 [16]. RNA-seq data from heart tissue samples of four participants without HCM and five participants with HCM are included in the GSE89714 dataset. The HiSeq 2000 platform was used for the sequencing experiment. The Cufflinks programme was employed to assess gene expression. Table 1 summarises the two datasets.

The cut-off criteria were set at $P < 0.05$ and $|\log \text{FC}| \geq 1.0$ to identify significant DEGs in each dataset using the DESeq2 R package. Jvenn online software was used to obtain the shared DEGs between GSE147507 and GSE89714 [17]. DEG expression was considered exclusive between the two datasets if statistically significant differences existed across different conditions [18].

2.2. Gene Ontology (GO) and Pathway Enrichment Analyses. Genome enrichment analysis helps determine the chromosome positions associated with various interrelated diseases [19]. We used an online tool, Enrichr (https://maayanlab.cloud/Enrichr/), to determine the possible molecular pathways and mechanisms involving the common DEGs. The shared pathways between HCM and COVID-19 were examined using four databases: BioCarta, WikiPathways, Reactome, and Kyoto Encyclopedia of Genes and Genomes (KEGG). A $P$ value of $< 0.05$ was used as a standard metric in quantifying the top-ranked pathways.

2.3. Protein-Protein Interaction (PPI) Network Analysis. The interaction of different cellular proteins can indirectly reflect a protein’s functions and roles. Understanding PPI networks can therefore shed light on how proteins function across the board in cellular machinery [20–23]. The shared DEGs were uploaded to the STRING database (https://string-db.org/) [21] to illustrate potential protein connections between HCM and COVID-19. The common DEG PPI network was created using a low confidence score of 0.15. The obtained PPI network was viewed using Cytoscape software (v.3.8.0).

2.4. Hub Gene Extraction and Submodule Analysis. Cytohubba, a validated Cytoscape plugin, ranks and extracts central or targeted elements based on numerous network features. Maximal clique centrality is a commonly used algorithm in Cytohubba for analysing networks from various perspectives [24, 25]. The top 10 hub genes in the obtained PPI network were identified using this method. Additionally, we classified the shortest paths between hub genes based on the calculations from Cytohubba.

2.5. Recognition of Transcription Factors (TFs) and MicroRNAs (miRNAs). A TF is a protein that binds to gene elements and regulates gene expression [26]. Candidate TFs that are topologically connected to mutual DEGs obtained from the JASPAR database were identified using the NetworkAnalyst platform, a popular web tool for the meta-analysis of gene expression data and viewing biological mechanisms, roles, and gene translation (https://www.networkanalyst.ca/) [27]. JASPAR provides open-access profiles of various TFs in six taxonomic groups [28]. In addition, TarBase and miRTarBase were used to analyse miRNA-targeted gene interactions to find miRNAs that potentially influence gene translation [29, 30]. These online tools can be used by researchers to filter high-degree miRNAs and identify the associated biochemical processes and characteristics to generate the most plausible hypothesis.

2.6. Prediction of Candidate Drugs. Predicting protein-drug interactions (PDIs) or identifying candidate drug molecules was a crucial aspect of this study. Enrichr was used to select potential drug molecules based on the identified DEGs in HCM and COVID-19 and the Drug Signatures database (DSigDB). Gene set libraries enabled by Enrichr allow users to study gene set enrichment at the genome-wide level [31]. Targeted drug substances connected to DEGs were identified using the DSigDB (https://maayanlab.cloud/Enrichr/) [32].

2.7. Gene and Disease Association Analysis. The DisGeNET database links various biomedical aspects of medical conditions with gene-disease relations. It focuses on our growing
3. Results

3.1. Identification of DEGs and Common DEGs. Patients with COVID-19 exhibited a differential expression of 1,781 genes, including 1,390 upregulated and 391 downregulated genes after disease exposure. Similarly, various statistical analysis techniques were used to rank the DEGs identified for HCM. All DEGs were identified using a criterion of \( P < 0.05 \) and \( \log_{10}(FC) \geq 1 \). Using the Jvenn online platform, 30 common DEGs were identified between the two datasets (Figure 1). There was a close relationship between the two diseases as they shared several genes [34].

3.2. GO and Pathway Enrichment Analyses. Using Enrichr, GO and pathway enrichment analyses were performed. Table 2 summarises the top 10 GO terms in the biological processes, molecular functions, and cellular component categories. DEGs are listed in increasing order based on \( P \) value. Figure 2 summarises the linear comparison of the overall ontological analysis of each category. An organism’s active pathways reveal how it responds to its inherent modifications. It illustrates the interaction between diseases through basic molecular processes [35]. We examined four global databases, KEGG, WikiPathways, Reactome, and BioCarta, to determine the most important pathways involving the DEGs common to HCM and COVID-19. Table 3 summarises the critical pathways identified based on the examined datasets. Pathway enrichment analysis was performed on the datasets (Figure 3). DEGs are listed in increasing order based on \( P \) value. A \( P \) value of \(< 0.05\) was used to determine the top functional items and pathways.

3.3. Classification of Hub Proteins and Submodules. We predicted the interaction of DEGs by analysing the STRING PPI network using Cytoscape. The PPI network constructed using the common DEGs comprised 30 nodes and 124 edges (Figure 4). Additionally, most of the interconnected nodes in the PPI network were identified as hub genes. Using the Cytohubba plugin, the top 10 DEGs were considered hub genes. This gene list includes thrombospondin 2 (THBS2), biglycan (BGN), collagen type I alpha 2 chain (COLIA2), actin alpha 2 (ACTA2), myosin heavy chain 11 (MYH11), adipocyte enhancer-binding protein 1 (AEBP1), immunoglobulin superfamily containing leucine-rich repeat (ISLR), frizzled-related protein (FRZB), microfibril-associated protein 4 (MFAP4), and lysyl oxidase homolog 1 (LOXL1). These hub genes might be used as biomarkers to identify diseases and develop new therapeutic approaches. To comprehend the connections between the hub genes, we also constructed a submodule network using the Cytohubba plugin (Figure 5).

3.4. Determination of Regulatory Signatures. There is a network-based approach to identify the transcriptional changes, identify the regulatory TFs and miRNAs, and gain insights into the molecules that regulate hub proteins or common DEGs. Figure 6 illustrates the interactions between the regulatory TFs and DEGs. Figure 7 illustrates the interactions between miRNA regulators and DEGs. According to the analyses of the TF-gene and miRNA-gene interaction networks, 41 TFs and 19 posttranscriptional miRNA signatures regulated more than one DEG, proving that they actively competed with one another.

3.5. Prediction of Candidate Drugs. Understanding the factors responsible for receptor sensitivity requires an assessment of PDIs [36, 37]. We used Enrichr to identify four potential drug molecules for HCM and COVID-19 provided by DSigDB. Based on the \( P \) value, the top four candidate compounds were extracted. Table 4 lists the most effective drugs identified.

3.6. Determination of Disease Association. Similarities in gene expression between the two conditions can be used to infer disease association and correlation [36, 37]. The first step toward developing therapeutic intervention strategies for diseases is identifying gene-disease relationships [38]. We found that degenerative polyarthritis, hyperkyphosis, and platyspondyly were highly correlated with the hub genes.

### Table 1: A description of the two datasets with their GEO information.

| Disease name | GEO accession | GEO platform | Total DEG count | Upregulated DEG count | Downregulated DEG count |
|--------------|----------------|--------------|-----------------|----------------------|------------------------|
| SARS-CoV-2   | GSE147507      | GPL18573     | 1781            | 1390                 | 391                    |
| HCM          | GSE89714       | GPL11154     | 207             | 134                  | 73                     |

Abbreviations: GEO: Gene Expression Omnibus; DEGs: differentially expressed genes; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; HCM: hypertrophic cardiomyopathy.
of HCM and COVID-19 (Figure 8). These conditions are complex and multifactorial. Its pathophysiology is influenced by alterations in cell structure, barriers, and environmental factors.

4. Discussion

HCM is a common genetic cardiovascular disease that may lead to heart failure. SARS-CoV-2 also infected cardiac cells expressing ACE2, thereby advancing heart failure [39]. Individuals with cardiomyopathy are at high risk of SARS-CoV-2 infection. Herein, we identified molecular targets that could serve as COVID-19 biomarkers. Additionally, these markers might provide crucial details about how they contribute to diseases and conditions. In biomedicine and systems biology research, the expression profiling of high-throughput sequencing data is useful for identifying potential biomarkers [40]. Recently, RNA-seq, a new sequencing method, has significantly improved our ability to examine gene fusions, mutations/single nucleotide polymorphism posttranscriptional modifications, and differential gene expression analyses [41]. As advances in high-throughput sequencing technologies are made, it is becoming more challenging to cope with the increasing bioinformatics data.

### Table 2: Gene ontology analysis of common differentially expressed genes between hypertrophic cardiomyopathy and coronavirus disease 2019.

| Category                        | GO ID      | Term                                    | P values     | Genes                        |
|---------------------------------|------------|-----------------------------------------|--------------|------------------------------|
| GO biological process           | GO:0006939 | Smooth muscle contraction               | 1.10E-06     | ACTA2, EDNRA, and MYH11     |
|                                 | GO:0014829 | Vascular-associated smooth muscle        | 6.06E-05     | ACTA2, EDNRA                 |
|                                 | GO:0048251 | Elastic fiber assembly                   | 6.06E-05     | MFP4, MYH11                  |
|                                 | GO:0030198 | Extracellular matrix assembly            | 7.69E-05     | COL1A2, BGN, CYP1B1, TIMP1, and LOXL1 |
|                                 | GO:004666  | Membrane lipid catabolic process         | 9.71E-05     | ENPP2, CYP1B1                |
|                                 | GO:0042310 | Vasoconstriction                         | 0.000118625  | ACTA2, EDNRA                 |
|                                 | GO:0097435 | Supramolecular fiber organization        | 0.000160702  | MFP4, COL1A2, CYP1B1, MYH11, and LOXL1 |
|                                 | GO:0030199 | Collagen fibril organization             | 0.000317018  | COL1A2, CYP1B1, and LOXL1   |
|                                 | GO:0085029 | Extracellular matrix assembly            | 0.000588116  | MFP4, MYH11                  |
|                                 | GO:0055013 | Cardiac muscle cell development          | 0.000588116  | MYH11, MYLK3                 |

#### GO biological process

| Category                        | GO ID      | Term                                    | P values     | Genes                        |
|---------------------------------|------------|-----------------------------------------|--------------|------------------------------|
|                                 | GO:0005105 | Type 1 fibroblast growth factor receptor binding | 0.007478193  | FGF18                        |
|                                 | GO:0005111 | Type 2 fibroblast growth factor receptor binding | 0.007478193  | FGF18                        |
|                                 | GO:0004528 | Phosphodiesterase I activity             | 0.007478193  | ENPP2                        |
|                                 | GO:0101020 | Estrogen 16-alpha-hydroxylase activity   | 0.011939153  | CYP1B1                       |
|                                 | GO:002020  | Protease binding                         | 0.013479908  | COL1A2, TIMP1                |
|                                 | GO:0048407 | Platelet-derived growth factor binding   | 0.016380734  | COL1A2                       |
|                                 | GO:0031432 | Titin binding                            | 0.019331061  | ANKRD1                       |
|                                 | GO:0008191 | Metalloendopeptidase inhibitor activity  | 0.020803015  | TIMP1                        |
|                                 | GO:0042288 | MHC class I protein binding              | 0.025206075  | TUBB4B                       |
|                                 | GO:0031690 | Adrenergic receptor binding              | 0.025206075  | ARRDC3                       |

#### GO molecular function

| Category                        | GO ID      | Term                                    | P values     | Genes                        |
|---------------------------------|------------|-----------------------------------------|--------------|------------------------------|
|                                 | GO:0062023 | Collagen-containing extracellular matrix | 6.41E-08     | MFP4, COL1A2, ABI3BP, BGN, PLAT, AEBP1, THBS2, and LOXL1 |
|                                 | GO:0031091 | Platelet alpha granule                   | 0.000327618  | ISLR, TIMP1, and THBS2       |
|                                 | GO:0034774 | Secretory granule lumen                  | 0.001211585  | C3, ISLR, TIMP1, and TUBB4B  |
|                                 | GO:0005775 | Vacuolar lumen                           | 0.001772031  | C3, BGN, and TUBB4B          |
|                                 | GO:0031093 | Platelet alpha granule lumen             | 0.004526565  | ISLR, TIMP1                  |
|                                 | GO:0071953 | Elastic fiber                            | 0.007478193  | MFP4                         |
|                                 | GO:0035578 | Azurophil granule lumen                  | 0.008026824  | C3, TUBB4B                   |
|                                 | GO:0005788 | Endoplasmic reticulum lumen              | 0.008747528  | C3, COL1A2, and TIMP1        |
|                                 | GO:0001527 | Microfilbril                             | 0.016380734  | MFP4                         |
|                                 | GO:0005859 | Muscle myosin complex                    | 0.022272833  | MYH11                        |
obtained using traditional biological methods. All these limitations may be solved by approaches with artificial intelligence [42].

In this study, our transcriptome analyses revealed that 30 DEGs share similar expression patterns between HCM and COVID-19. GO pathway analysis was performed to obtain insights into the biological significance of the common DEGs in disease progression. The smooth muscle contraction pathway and vascular-associated smooth muscle contraction pathway were among the top GO terms identified for the biological process. There is a strong correlation between smooth muscle contraction and SARS-CoV-2 infection, according to several studies. Dysfunction endothelial cells prevent the release of adequate nitrogen oxide (NO), causing smooth muscle constriction [43] and reducing the cells’ ability to neutralise reactive oxygen species and release NO [44, 45]. The top two GO pathways identified in the molecular function category are types 1 and 2 fibroblast growth factor receptor binders. Cardiac hypertrophy in the postnatal period has been linked to the FGF family, and activating mutations in FGF receptor-1 have been shown to cause HCM [46]. The release of proinflammatory...
### Table 3: Pathway enrichment analysis of common differentially expressed genes between hypertrophic cardiomyopathy and coronavirus disease 2019.

| Category          | Pathways                                                                 | P values      | Genes                                                                 |
|-------------------|--------------------------------------------------------------------------|---------------|----------------------------------------------------------------------|
| WikiPathways human| **IL-18 signaling pathway WP4754**                                        | 4.84E-05      | ACTA2, BTG2, COL1A2, TIMP1, and IER3                                  |
|                   | Endochondral ossification with skeletal dysplasias WP4808               | 0.000119283   | FRZB, FGF18, and PLAT                                                  |
|                   | Endochondral ossification WP474                                          | 0.000119283   | FRZB, FGF18, and PLAT                                                  |
|                   | miR-509-3p alteration of YAP1/ECM axis WP3967                            | 0.000291693   | EDNRA, THBS2                                                           |
|                   | miRNA targets in ECM and membrane receptors WP2911                      | 0.000493146   | COL1A2, THBS2                                                           |
|                   | Focal adhesion-P13K-Akt-mTOR-signaling pathway WP3932                   | 0.00103726    | COL1A2, FGF18, THBS2, FGF12                                            |
|                   | P13K-Akt signaling pathway WP4172                                        | 0.001585899   | COL1A2, FGF18, THBS2, and FGF12                                       |
|                   | Focal adhesion WP306                                                      | 0.003186561   | COL1A2, THBS2, and MYLK3                                               |
|                   | Complement and coagulation cascades WP558                               | 0.003412595   | C3, PLAT                                                              |
|                   | Genotoxicity pathway WP4286                                              | 0.004013249   | ACTA2, BTG2                                                            |
| BioCarta           | Inhibition of matrix metalloproteinases h reckPathway                   | 0.011939153   | TIMP1                                                                 |
|                   | BTG family proteins and cell cycle regulation h bg2Pathway              | 0.013421829   | BTG2                                                                  |
|                   | Alternative complement pathway h alternativePathway                     | 0.014902355   | C3                                                                    |
|                   | Lectin induced complement pathway h lectinPathway                       | 0.019331061   | C3                                                                    |
|                   | Platelet amyloid precursor protein pathway h plateletAppPathway          | 0.020803015   | PLAT                                                                  |
|                   | Classical complement pathway h classicPathway                            | 0.022272833   | C3                                                                    |
|                   | Fibrinolysis pathway h fibrinolysisPathway                               | 0.022272833   | PLAT                                                                  |
|                   | Beta-arrestins in GPCR desensitization h bArrestinPathway               | 0.041187484   | EDNRA                                                                 |
|                   | Activation of cAMP-dependent protein kinase, PKA h gpPathway            | 0.042627715   | EDNRA                                                                 |
|                   | Role of Beta-arrestins in the activation and targeting of MAP kinases h path-makPathway | 0.044065855   | EDNRA                                                                 |
| KEGG 2019 human   | Vascular smooth muscle contraction                                       | 4.48E-05      | ACTA2, EDNRA, MYH11, and MYLK3                                        |
|                   | Apelin signaling pathway                                                 | 0.001114898   | ACTA2, PLAT, and MYLK3                                                 |
|                   | Phagosome                                                                | 0.001503079   | C3, THBS2, and TUBB4B                                                  |
|                   | Focal adhesion                                                           | 0.003324312   | COL1A2, THBS2, and MYLK3                                               |
|                   | Regulation of actin cytoskeleton                                         | 0.004174068   | FGF18, MYH11, and MYLK3                                                 |
|                   | Calcium signaling pathway                                                | 0.005454596   | EDNRA, FGF18, and MYLK3                                                 |
|                   | Complement and coagulation cascades                                       | 0.007187738   | C3, PLAT                                                              |
|                   | ECM-receptor interaction                                                 | 0.007685775   | COL1A2, THBS2                                                           |
|                   | Platelet activation                                                      | 0.014809355   | COL1A2, MYLK3                                                          |
|                   | PI3K-Akt signaling pathway                                               | 0.015674766   | COL1A2, FGF18, and THBS2                                              |
| Reactome          | Extracellular matrix organization R-HSA-1474244                         | 5.84E-05      | MFAP4, COL1A2, BGN, TIMP1, and LOXL1                                  |
|                   | Smooth muscle contraction R-HSA-445355                                   | 0.0011157     | ACTA2, MYH11                                                           |
|                   | Elastic fiber formation R-HSA-1566948                                    | 0.001719859   | MFP4, LOXL1                                                           |
|                   | Signaling by PDGF R-HSA-186797                                          | 0.002034436   | FGF18, PLAT, THBS2, and IER3                                           |
|                   | Assembly of collagen fibrils and other multimeric structures R-HSA-2022090 | 0.002965286   | COL1A2, LOXL1                                                          |
|                   | Muscle contraction R-HSA-397014                                          | 0.003096721   | ACTA2, MYH11, and FGF12                                               |
|                   | PISP, PP2A, and IER3 regulate PI3K/AKT signaling R-HSA-6811558          | 0.006864228   | FGF18, IER3                                                           |
|                   | Collagen formation R-HSA-1474290                                         | 0.007187738   | COL1A2, LOXL1                                                          |
|                   | Diseases of glycosylation R-HSA-3781865                                 | 0.007685775   | BGN, THBS2                                                            |
|                   | Negative regulation of the PI3K/AKT network R-HSA-199418                | 0.008026254   | FGF18, IER3                                                           |
**Figure 3:** Pathway enrichment analysis of the common differentially expressed genes between hypertrophic cardiomyopathy and coronavirus disease 2019 was performed using Enrichr. Different databases were used in the analysis: (a) WikiPathways, (b) BioCarta, (c) Reactome, and (d) Kyoto Encyclopedia of Genes and Genomes 2019 human database.
cytokines, such as interleukin-(IL-) 9, IL-10, type 1 FGF, and type 2 FGF, was found in excessive and uncontrolled quantities in critically ill COVID-19 patients [47]. These cytokines are considered valuable biomarkers for evaluating disease progression and potential biological therapeutic targets currently being investigated. In the cellular component category, the top GO terms identified using the common DEGs were collagen-containing extracellular matrix (ECM) and platelet alpha granule. Similarly, the Reactome analysis of the DEGs was mainly enriched in ECM organization (R-HSA-1566948). The ECM comprises fibrillar structures that are made of collagen. Cardiorespiratory disease has been linked to collagen dysfunction [48].

We developed a PPI network based on the identified DEGs to understand how proteins behave biologically and predict potential drug targets. Herein, we used the topological metric (i.e., degree) to identify hub proteins that could serve as COVID-19 potential drug targets or biomarkers and could be linked to various pathological and cellular mechanisms. Most of the top hub proteins identified are associated with HCM and COVID-19 risk factors. These diseases have been linked to ten hub-protein products, including THBS2, BGN, COL1A2, ACTA2, MYH11, AEBP1, ISLR, FRZB, MFAp4, and LOX1. In this study, a cut-off parameter of 12 degrees was used to identify hub proteins. Cardiorespiratory diseases are significantly impacted by the THBS family of proteins. The effects of circular RNA knockdown on the growth, migration, and necrosis of lung cancer cells are reversed by the overexpression of THBS2, a miR-590-5 target [49]. Additionally, this gene was linked to adenovirus infection [50] and could function as one of COVID-19’s possible therapeutic targets. Meanwhile, THBS1 and COL1A1 are genes involved in cardiac remodelling, a hallmark of cardiac hypertrophy [51]. Lastly, BGN ubiquitously exists in the intestinal ECM; thus, BGN could potentially serve as a therapeutic target for HCM patients with COVID-19.

Herein, the TF-gene and miRNA interactions were also analysed to identify potential transcriptional regulators of the common DEGs. TFs and miRNAs regulate gene expression and posttranscriptional RNA silencing, two processes that are crucial to understanding disease development. We discovered connections between the common DEGs, TFs, and miRNAs. The identified TFs, such as the GATA-binding factor 2, histone H4 TF, TF AP-2 alpha, nuclear factor kappa B subunit 1, BGN, and forhead box C 1, were found to relate to different types of developmental and hereditary diseases. Moreover, most of the miRNAs involved in various cancer types (e.g., hsa-mir-29c-3p, hsa-mir-1-3p, and hsa-mir-128-3p) [52–54] and immunity disorders (e.g., hsa-mir-129-2-3p, hsa-mir-16-5p, hsa-mir-182-5p, hsa-mir-27b-3p, and hsa-mir-124-3p) [55–59], as well as TFs related to the corresponding genes, target major proteins to alter their role in disease progression. For example, hsa-mir-29c-3p, hsa-mir-1-3p, and hsa-mir-129-2-3p have been found to target THBS2 [52, 53, 55]. Four miRNAs that we predicted—hsa-mir-376a-5p, hsa-mir-30a-5p, hsa-mir-23b-3p, and hsa-mir-27a-5p—were found to be associated with various HCM-related genes [60–63]. Many of the miRNAs identified are linked to several cancer types, especially lung cancer.

The DEGs and their relation to various diseases were analysed using a gene-disease analysis. Our findings for COVID-19 revealed the involvement of several diseases, such as lung cancer, cardiovascular diseases, blood disorders, liver ailments, and blood coagulation disorders. According to some reviews, SARS-CoV-2 could exacerbate the pathological process of degenerative osteoarthritis. ACE2 expression, RAS imbalances, in inflammation, and dysfunction at the molecular level have been suggested as the causative factors [64]. Based on the aforementioned reports, we speculate that systemic inflammation and ischaemia could aggravate cardiac injury in patients with HCM. Hence, anti-inflammatory therapy is particularly important for patients with COVID-19 and HCM.

Herein, we identified dasatinib, a tyrosine kinase inhibitor used for leukaemia. Previous reports predicted that dasatinib could inhibit the binding of SARS-CoV-2 spike protein to ACE2 [65]. However, dasatinib has not yet been previously reported as a treatment option for patients with HCM. By boosting the activation of the mammalian target of rapamycin complex 2, rapamycin, another drug candidate discovered, may be used to reduce inflammation in patients with heart disease [66]. Meanwhile, another drug, decitabine, could increase neoantigen expression to enhance T cell-mediated toxicity against glioblastoma [67]. Testosterone enanthate replacement therapy is commonly used in patients with low testosterone [68]. Additionally, testosterone administration helps suppress the inflammatory response [69] and modulates the immune response, which would be more significant in female patients. We witnessed the first case of corticosteroid and tocilizumab application in reversing the severely reduced left ventricular systolic...
Figure 5: Determination of hub genes from the protein-protein interaction network using the latest maximal clique centrality procedure with the Cytohubba plugin in Cytoscape. The nodes highlighted in red or yellow represent the top 10 hub genes and their interactions with other molecules. There are 26 nodes and 119 edges in the network.

Figure 6: Differentially expressed gene-transcription factor (TF) regulatory interactions were constructed based on our analyses. The nodes in this diagram represent the TFs, while circular nodes are gene symbols that interact with the TFs.
function due to myocardial depression caused by COVID-19 [70]. This partially demonstrates the clinical viability of our candidate drugs in patients with HCM and paves the way for future pharmaceutical studies. Although we could identify candidate drugs based on our bioinformatics analyses, the findings are also limited in that no experiments or further analytical validation were performed on the data obtained. These reasons could lead to unreliable and imprecise conclusions. Thus, further experiments or clinical trials are necessary to validate their effectiveness and safety.

5. Conclusions

As the COVID-19 vaccine becomes more widely used, more side effects are being reported [71]. Despite the ongoing
development of numerous COVID-19 vaccines, mutant
SARS-CoV-2 strains continue to appear. According to this
study’s bioinformatics analysis, the 10 most important genes
that HCM and COVID-19 have in common are
THBS2, BGN, COL1A2, ACTA2, MYH11, AEBP1, ISLR, FRZB,
MFAP4, and LOXL1. Each of these hub genes is essential
for various functional mutation developments. Therefore,
we used transcriptomic analysis to identify shared pathways
and molecular biomarkers between HCM and COVID-19,
which could aid in COVID-19 vaccine development and
the discovery of novel therapeutic targets.

Data Availability

The data used to support the findings of this study are
included in the article.

Conflicts of Interest

The authors declare that they have no competing interests.

Authors’ Contributions

Xiao Han and Fei Wang contributed equally to this work.

References

[1] Y. Y. Zheng, Y. T. Ma, J. Y. Zhang, and X. Xie, “COVID-19 and
the cardiovascular system,” Nature Reviews Cardiology, vol. 17,
no. 5, pp. 259-260, 2020.

[2] V. C. C. Cheng, S. K. P. Lau, P. C. Y. Woo, and K. Y. Yuen,
“Severe acute respiratory syndrome coronavirus as an agent
of emerging and reemerging infection,” Clinical Microbiology
Reviews, vol. 20, no. 4, pp. 660–694, 2007.

[3] R. Lu, X. Zhao, J. Li et al., “Genomic characterisation and epi-
demiology of 2019 novel coronavirus: implications for virus
origins and receptor binding,” Lancet, vol. 395, no. 10224,
pp. 565–574, 2020.

[4] A. Saghaazadeh and N. Rezaei, “Immune-epidemiological
parameters of the novel coronavirus - a perspective,” Expert
Review of Clinical Immunology, vol. 16, no. 5, pp. 465–470,
2020.

[5] C. Huang, Y. Wang, X. Li et al., “Clinical features of patients
infected with 2019 novel coronavirus in Wuhan, China,” The
Lancet, vol. 395, no. 10223, pp. 497–506, 2020.

[6] E. Driggin, M. V. Madhavan, B. Bikdeli et al., “Cardiovascular
considerations for patients, health care workers, and health
systems during the COVID-19 pandemic,” Journal of the
American College of Cardiology, vol. 75, no. 18, pp. 2352–
2371, 2020.

[7] A. Lala, K. W. Johnson, J. L. Januzzi et al., “Prevalence and
impact of myocardial injury in patients hospitalized with
COVID-19 infection,” Journal of the American College of Car-
diology, vol. 76, no. 5, pp. 533–546, 2020.

[8] A. Hessami and N. Rezaei, “Cardiovascular diseases burden in
COVID-19,” The American Journal of Emergency Medicine,
vol. 50, p. 790, 2021.

[9] S. R. Ommen, S. Mital, M. A. Burke et al., “2020 AHA/ACC
guideline for the diagnosis and treatment of patients with
hypertrophic cardiomyopathy: a report of the American Col-
lege of Cardiology/American Heart Association Joint Com-
mittee on Clinical Practice Guidelines,” The Journal of
Thoracic and Cardiovascular Surgery, vol. 162, no. 1,
pp. e23–e106, 2021.

[10] N. Z. Cuervo and N. Grandvaux, “ACE2: evidence of role as
entry receptor for SARS-CoV-2 and implications in comorbid-
ities,” elife Sciences, vol. 9, 2020.

[11] D. Chen, X. Li, Q. Song et al., “Assessment of hypokalemia and
clinical characteristics in patients with coronavirus disease
replication: viral RNA production and palmitoylation of the S protein are affected,” *Virology*, vol. 395, no. 1, pp. 1–9, 2009.

[45] S. Akerström, M. Mousavi-Jazi, J. Klingström, M. Leijon, A. Lundkvist, and A. Mizraimi, “Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus,” *Journal of Virology*, vol. 79, no. 3, pp. 1966–1969, 2005.

[46] S. N. Cilvik, J. I. Wang, K. J. Lavine et al., “Fibroblast growth factor receptor 1 signaling in adult cardiomyocytes increases contractility and results in a hypertrophic cardiomyopathy,” *PLoS One*, vol. 8, no. 12, p. e82979, 2013.

[47] M. Cao, D. Zhang, Y. Wang et al., “Clinical features of patients infected with the 2019 novel coronavirus (COVID-19) in Shanghai, China,” medRxiv, 2020.

[48] S. E. Dunsmore, “Extracellular matrix | collagens,” *Encyclopedia of Respiratory Medicine*, pp. 168–175, 2006.

[49] L. Wang, L. Zhao, and Y. Wang, “Circular RNA circ_0020123 promotes non-small cell lung cancer progression by sponging miR-590-5p to regulate THBS2,” *Cancer Cell International*, vol. 20, no. 1, 2020.

[50] Y. Inagaki and I. Okazaki, “Emerging insights into transforming growth factor beta Smad signal in hepatic fibrogenesis,” *Gut*, vol. 56, no. 2, pp. 284–292, 2007.

[51] S. Sezaki, S. Hirohata, A. Ishubu et al., “Thrombospondin-1 is induced in rat myocardial infarction and its induction is accelerated by ischemia/reperfusion,” *Experimental Biology & Medicine*, vol. 230, no. 9, pp. 621–630, 2005.

[52] S. Zhang, X. Xiang, L. Liu, H. Yang, D. Cen, and G. Tang, “Bioinformatics analysis of hub genes and potential therapeutic agents associated with gastric cancer,” *Cancer Management and Research*, vol. 13, no. 13, pp. 8929–8951, 2021.

[53] L. Zhang, S. Hu, J. Chen et al., “Comprehensive analysis of the MIR4435-2HG/miR-1-3p/MMP9/miR-29-3p/DUXAP8 ceRNA network axis in hepatocellular carcinoma,” *Discover Oncology*, vol. 12, no. 1, p. 38, 2021.

[54] T. Zheng, W. Han, A. Wang, and Y. Wang, “Functional mechanism of hsa-miR-128-3p in epithelial-mesenchymal transition of pancreatic cancer cells via ZEB1 regulation,” *PeerJ*, vol. 10, no. 10, article e12802, 2022.

[55] A. Gholaminejad, A. Roojntan, and Y. Gheisari, “Transmembrane signaling molecules play a key role in the pathogenesis of IgA nephropathy: a weighted gene co-expression network analysis study,” *BMC Immunology*, vol. 22, no. 1, p. 73, 2021.

[56] C. Li, R. Wang, A. Wu et al., “SARS-COV-2 as potential microRNA sponge in COVID-19 patients,” *BMC Medical Genomics*, vol. 15, Supplement 2, p. 94, 2022.

[57] V. Gryshkova, I. Lushbough, J. Palmer et al., “MicroRNAs signatures as potential biomarkers of structural cardiotoxicity in human-induced pluripotent stem-cell derived cardiomyocytes,” *Archives of Toxicology*, vol. 96, no. 7, pp. 2033–2047, 2022.

[58] J. Yu, X. Kang, Y. Xiong, Q. Luo, D. Dai, and J. Ye, “Gene expression profiles of circular RNAs and microRNAs in chronic rhinosinusitis with nasal polyps,” *Frontiers in Molecular Biosciences*, vol. 8, no. 8, article 643504, 2021.

[59] L. Wu, X. Tian, H. Zuo et al., “miR-124-3p delivered by exosomes from heme oxygenase-1 modified bone marrow mesenchymal stem cells inhibits ferroptosis to attenuate ischemia-reperfusion injury in steatotic grafts,” *Journal of Nanobiotechnology*, vol. 20, no. 1, p. 196, 2022.

[60] B. Zhang, X. Tian, Z. Qu, J. Hao, and W. Zhang, “Hypoxia-preconditioned extracellular vesicles from mesenchymal stem cells improve cartilage repair in osteoarthritis,” *Membranes*, vol. 12, no. 2, p. 225, 2022.

[61] W. Chen, H. Wang, T. Li et al., “A novel prognostic model for hepatocellular carcinoma based on 5 microRNAs related to vascular invasion,” *BMC Medical Genomics*, vol. 15, no. 1, p. 34, 2022.

[62] H. B. Sun, G. C. Zhang, J. Liu, and C. S. Nie, “Long noncoding RNA LINC00184 facilitates the proliferation, metastasis, and adenoine metabolism of cholangiocarcinoma via modulating hsa-miR-23b-3p/ANXA2 axis,” *Environmental Toxicology*, vol. 36, no. 8, pp. 1576–1590, 2021.

[63] D. E. Magouliotis, M. P. Fergadi, G. Christoudoulidis et al., “In-depth bioinformatic study of the cadherin 5 interactome in patients with thoracic aortic aneurysm unveils 8 novel biomarkers,” *European Journal of Cardio-Thoracic Surgery*, vol. 61, no. 1, pp. 11–18, 2021, PMID: 34293135.

[64] M. Lauwers, M. Au, S. Yuan, and C. Wen, “COVID-19 in joint ageing and osteoarthritis: current status and perspectives,” *International Journal of Molecular Sciences*, vol. 23, no. 2, p. 720, 2022.

[65] A. Bahadur Gurung, M. Ajmal Ali, M. S. Elshikh, I. Aref, M. Amina, and J. Lee, “An in silico approach unveils the potential of antiviral compounds in preclinical and clinical trials as SARS-CoV-2 Omicron inhibitors,” *Saudi Journal of Biological Sciences*, vol. 29, no. 6, article 103297, 2022.

[66] X. Gu, R. Weng, J. Hou, and S. Liu, “Endothelial miR-199a-3p regulating cell adhesion molecules by targeting mTOR signaling during inflammation,” *European Journal of Pharmacology*, vol. 925, p. 174984, 2022, Epub ahead of print.

[67] R. Ma, M. Rei, I. Woodhouse et al., “Decitabine increases neoantigen and cancer testis antigen expression to enhance T-cell-mediated toxicity against glioblastoma,” *Neuro-oncology*, no. article noa107, 2022.

[68] F. Chen, H. Lu, P. Chen et al., “Acute effects of the translocator protein drug ligand FG-1-27 on serum testosterone and luteinizing hormone levels in male Sprague-Dawley rats,” *Biolog Reproduction*, vol. 100, no. 3, pp. 824–832, 2019.

[69] C. J. Malkin, P. J. Pugh, R. D. Jones, D. Kapoor, K. S. Channer, and T. H. Jones, “The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men,” *The Journal of Clinical Endocrinology and Metabolism*, vol. 89, no. 7, pp. 3313–3318, 2004.

[70] A. Schreiber, K. Elango, S. Soussu, S. Fakhr, S. Asad, and C. Ahsan, “COVID-19 induced cardiomyopathy successfully treated with tocilizumab,” *Case Reports in Cardiology*, vol. 2022, Article ID 9943937, 6 pages, 2022.

[71] C. Menni, K. Klasar, A. May et al., “Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID symptom study app in the UK: a prospective observational study,” *The Lancet Infectious Diseases*, vol. 21, no. 7, pp. 939–949, 2021.